logo
Cash as medicine: How Brazil slashed TB by tackling poverty

Cash as medicine: How Brazil slashed TB by tackling poverty

Yahoo10-02-2025

Crislaine Souza lives with her husband and one-year-old son in a rural community in Ourolândia, a municipality in Brazil's north-east that suffered centuries of neglect.
She is unemployed and, though her husband works as an electrician and does what he can to support his wife and children, the family is among the poorest in the country.
The family is on the brink – her husband and her one-year-old son are both deficient in iron, vitamin B12 and vitamin D – but it has a lifeline.
Every month, she receives government cash to spend on essentials like nutritious food, health supplements and gas for cooking.
Across Brazil, there are around 21 million other families in a similar situation, and they all receive monthly payments as part of the Bolsa Família scheme – one of the largest and longest-running conditional cash transfer programmes to be found anywhere.
Ms Souza has been on the programme for four months and receives about $120 (£97) in monthly support.
In return, she must ensure her children are vaccinated, attend school and meet nutrition guidelines. If she doesn't comply with these conditions, her payments could be stopped.
Her family regularly travel on foot along unpaved roads to a primary health clinic in Ourolândia to attend health checks.
'My son started taking supplements for anaemia and deficiencies and is happy, smiling and lively, very intelligent and developing well. I am dividing the supplements between him and my oldest daughter, because she eats little variety, so she needs them too,' she said.
Ms Souza worries about money, but says Bolsa Família has helped a lot.
'I feel more relieved knowing that I don't have to depend on my husband to buy everything. Just knowing that I'll have the money next month makes me feel more at ease, and I can be sure that I can resolve anything my children need.'
The programme was launched in 2003 by Luiz Inacio Lula da Silva, the Leftist president better known as Lula, with the goal of reducing poverty.
The politicians and experts behind the pioneering scheme never anticipated the remarkable effects it would have on the country's health.
In just over two decades, it has been credited with reducing new AIDS cases by over 40 per cent, cutting maternal mortality by 18 per cent, deaths from leprosy by 14 per cent, and preventing more than eight million hospitalisations.
But it has also been busy working its magic on the world's top infectious killer – tuberculosis.
Researchers from the Barcelona Institute for Global Health (ISGlobal), the Institute of Collective Health, and CIDACS-FIOCRUZ in Bahia, Brazil, analysed TB outcomes among 54 million low-income Brazilians.
What they found was a drop in TB cases and deaths by over 50 per cent among the extremely poor.
Cases and deaths among indigenous beneficiaries – whose income can double or even triple under Bolsa Família – fell by over 60 per cent.
Their findings, published recently in Nature Medicine, are a stark reminder that diseases of poverty cannot be addressed by scientific innovation alone.
Dr Davide Rasella, coordinator of the study and a Social Epidemiologist who has published extensively on Bolsa Família, said: 'These numbers are close to biomedical treatments like a new drug or vaccine.'
'We knew that giving $100 a month to someone earning $1 or $2 a day transforms their life dramatically, but we didn't expect the effect to be this strong.'
Yet the data doesn't tell us anything new about who is most at risk of falling ill or dying from TB, an ancient bacterium that attacks the lungs and has plagued humans for thousands of years. And this lack of revelation is precisely why policymakers should pay close attention.
Last year the WHO cautioned that the world will not hit its targets to cut TB without urgent technological breakthroughs.
But what use does a new vaccine serve to the labourer who cannot afford a taxi to the clinic?
'It's extremely important that from one side we invest in biomedical innovation, but we must be sure that the extremely poor live in the right conditions to take advantage of it,' Dr Rasella said.
Bolsa Família's success provides a case study on why medical innovation alone cannot address the structural barriers keeping healthcare out of reach for so many.
Is it possible for the rest of the world to replicate Brazil's approach?
Today, almost every country in the world operates a cash transfer programme, and their use in humanitarian settings has doubled in recent years. In Britain, we call them benefits. Across the pond, it's welfare.
Experts agree these schemes save lives and maximise the impact of medicine.
'Money is a necessary component for good health. Without money, you can't prevent disease or benefit from the great outcomes we know are possible with modern medicine,' said Dr Miriam Laker-Oketta, Research Director at GiveDirectly, a nonprofit that sends cash to the mobile phones of poor families.
Dr Rasella agrees: 'We are showing that it is fundamental to eradicate poverty to reduce the burden of disease in the poorest populations.'
Yet how cash transfers reach the people who need them matters, and so do the terms.
Brazil's central bank last year revealed that millions of beneficiaries had sent three billion reais (around £400 million) to online gambling companies.
The government later banned betting with benefits, adding another rule, or condition, beneficiaries must abide by. But what are conditions and why do they matter?
Mandatory vaccinations, health checks and minimum attendance at school are conditions that form the contract between beneficiary and state. They are what study authors Dr Rasella and Priscila Gestal believe the success of Bolsa Família hinges on.
Brazil's well-oiled administrative infrastructure makes conditions work. A central database, Cadastro Único, ensures cash goes to the neediest families, while local governments verify eligibility, monitor compliance, and deliver payments.
Even under welfare critic Jair Bolsonaro, the programme persisted under a new name.
But what would happen if Bolsa Familia cash came without strings? Ms Gestal said that without conditions, its impact would not be as strong.
'Conditions ensure people engage with public services for health and education. Child mortality reductions are linked to vaccinations, growth monitoring, and prenatal care. In the case of TB, mothers bringing children for check-ups may themselves get diagnosed and treated,' she said.
But Dr Laker-Oketta argues enforcement costs could go directly to families, and Jessica Hagen-Zanker, a Senior Research Fellow at ODI Global, said enforcing conditions isn't possible everywhere.
'Conditions can be expensive to administer, adding to the cost of the programme, and are ineffective in areas with insufficient or low-quality supply of services,' said Dr Hagen-Zanker.
For example, today more than 83 million people in Nigeria live in extreme poverty, and 45 per cent of all deaths in young children are linked to malnutrition.
Last year, Nigeria's Minister of Humanitarian Affairs and Disaster Management, Betta Edu, was removed from cabinet after she siphoned £500,000 of conditional cash transfer grants meant for the most vulnerable into a personal bank account.
What hope is there, then, for the millions of people living in countries where corruption or poor infrastructure make Bolsa Família's success impossible to replicate?
It's simple – just give cash without conditions directly to people who need it.
Nonprofit GiveDirectly gives cash without strings to the world's poorest families. Administrative overheads aren't a problem because payments are sent straight to mobile phones.
Rory Stewart, former Secretary of State for International Development and Advisor to GiveDirectly, said these programmes directly improve key indicators like health, education, and nutrition, while outperforming traditional aid interventions in cost effectiveness and long-term impact.
'In low-income countries, most health facilities are in urban centres, and underutilisation by the rural poor often boils down to costly travel time to health facilities,' he told The Telegraph.
But cash transfers can remove these barriers to access overnight.
'Cash makes it easier to get to health facilities and pay for medicines. After GiveDirectly sends cash, villages quickly fill up with bicycles and motor taxis. Families can now afford trips to the clinic and medicines they're prescribed.'
It isn't only the logistics of accessing healthcare that direct cash can improve. When people have money, they adopt healthy behaviours even if they aren't told to.
'In our Rwanda childhood nutrition programme, families who received unconditional cash without any other information were more likely to take up vaccinations,' Dr Laker-Oketta says. 'And in this same programme, cash led to a 70 per cent drop in child mortality.'
The key to this, Mr Stewart says, is quite simple – people know what is best for them.
'We spend tremendous time and money telling people what they should do to improve their health, ignoring that they are far too poor to act on this 'advice,' most of which they already know.'
So is private actor cash the answer, or just part of it? It depends on who you ask.
Economists argue that the only way to reduce global poverty and its associated diseases at scale, is by making poor countries more productive across the board.
William Easterly, Professor of Economics at NYU, said the evidence suggests cash grants help individuals but do not transform whole countries from poverty to prosperity.
'If a country is poor, it is often because of institutions like corruption and public mismanagement,' he said.
Lant Pritchett, a Development Economist and RISE Research Director at Oxford University's Blavatnik School of Government, agrees.
'My slogan is that the world is not full of poor people, it is full of people in poor places. National development is a machinery that nominates and solves people's problems, including health.'
But while GiveDirectly may not have the power to fix corrupt governments, its programmes are certainly generating interesting economic data.
'Cash transfer programmes consistently deliver a high return on investment, with some studies showing a multiplier effect – every dollar invested generates up to $2.50 in economic benefit,' said Mr Stewart.
In Brazil, Bolsa Família has slashed TB rates and prevented millions of deaths from infectious diseases by tying financial support to vaccinations, health check-ups, and school attendance.
GiveDirectly's programmes show how direct, no-strings cash can improve health and economic outcomes in ways even the most ambitious aid programmes have failed to achieve, especially in places with poor administrative infrastructure.
Dr Rasella, the study coordinator, said: 'You can't think about developing incredibly effective vaccines if the extremely poor can't access them because it's too far away, or their immune systems are too weak to respond to an antiretroviral because they're undernourished.'
Cash transfers may not be a cure-all, but they are one of the most simple and effective prescriptions we have to address the structural barriers that keep healthcare out of reach for so many.
In Ourolândia, the Bolsa Família payments that Ms Souza receives have allowed her to feel hopeful about the future.
'I want to go back to work, wait for my son to grow up and have a job, and maybe one day open a restaurant, that's one of my dreams.'
Protect yourself and your family by learning more about Global Health Security
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump to slash funding for flagship US HIV programme by 40pc
Trump to slash funding for flagship US HIV programme by 40pc

Yahoo

timean hour ago

  • Yahoo

Trump to slash funding for flagship US HIV programme by 40pc

America is proposing to cut its flagship anti-HIV programme by almost 40 per cent next year, according to new budget details that reveal sweeping reductions to global health spending. Details from Donald Trump's 2026 budget request show nearly a two-fifths fall in funding for the United States President's Emergency Plan for Aids Relief (Pepfar). The long-running programme is estimated to have saved more that 20 million lives in the past two decades, and is often cited as one of the world's most successful public health schemes. A recent analysis published in the Lancet found that as many as half a million more children could die from Aids by the end of the decade because of disruptions to Pepfar. The details on global health funding for the State Department, USAID agency, Centres for Disease Control and Prevention (CDC), and the National Institutes of Health (NIH) also show deep cuts elsewhere. Analysis by the San Francisco-based KFF health policy charity found the government departments were planning a 55 per cent cut in separate tuberculosis funding, a 47 per cent cut in malaria funding and a 92 per cent cut in maternal health funding. The proposal also withdraws all £221m ($300m) given to Gavi, the vaccine alliance which provides jabs to children in poor countries. In total, the request for money for the American government's main global health funding account is £2.8bn ($3.8bn) in 2026, down from £7.4bn ($10bn) in 2025. Setting out the cuts, the State Department said the request for money 'eliminates funding for programmes that do not make Americans safer, such as family planning and reproductive health, neglected tropical diseases, and non-emergency nutrition'. Mr Trump's government upended US aid spending days after taking office, saying it would suspend all aid while projects were reviewed. It then proceeded to close hundreds of aid programmes, including Pepfar projects, resulting in lay-offs for thousands of health workers, particularly in Africa. The budget proposals now give a clear indication that Mr Trump intends to continue with sharp cuts and will quash any hopes that the funding taps could be switched back on again. A State Department explanation of the budget request uses the phrase 'America First' 37 times as it explains a new focus on cutting costs and protecting US national interests. For the 2026 fiscal year, which begins on Oct 1, the budget proposals request £2.1bn ($2.9bn) for Pepfar, a 38 per cent reduction from the £3.5bn ($4.7bn) requested in 2025. The State department said that after spending a total of £88bn ($120bn) in the past two decades, it was now focussing on finding a responsible 'off ramp' to hand over responsibility for the campaign against HIV to countries themselves. 'This [budget] request will allow the United States to accelerate the transition of HIV control programmes to recipient countries and increase international ownership of efforts to fight HIV/Aids.' Some projects may still be paid for by other government funds, but overall the KFF analysis found the budget included 'significant reductions in global health funding including the elimination of some programs and activities'. The details will prove a severe disappointment to aid projects who had hoped that despite Mr Trump's rhetoric, there was a chance funding could be renewed in the new fiscal year. Public health officials argue that continuing to fund global health projects to stamp out infectious diseases is still in America's best interests as infections often cross borders. One executive at a major South African anti-HIV organisation said: 'Nobody wins unless we all win. No one can make it out of this alone. This is how we achieve epidemic control.' Protect yourself and your family by learning more about Global Health Security Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.

Experts Warn Of Decade-Long Setback After Trump Cuts HIV Vaccine Research
Experts Warn Of Decade-Long Setback After Trump Cuts HIV Vaccine Research

Forbes

time2 hours ago

  • Forbes

Experts Warn Of Decade-Long Setback After Trump Cuts HIV Vaccine Research

NEW YORK - DECEMBER 1: Marina Kemelman, Research Associate at the AIDS Vaccine Design and ... More Development Laboratory, collects bacteria transfected with DNA as part of research at the laboratory's campus in the former Brooklyn Army Terminal December 1, 2008 in New York City. The laboratory, seeking a vaccine to prevent the spread of AIDS, is part of the International AIDS Vaccine Initiative (or IAVI), a global not-for-profit, public-private partnership working to accelerate the development of a vaccine to prevent HIV infection and AIDS. December 1 is the 20th annual World AIDS Day around the world. (Photo by) It was a rare moment of bipartisan unity. Standing before a joint session of Congress in January 2019, President Donald Trump boldly pledged to eradicate a disease that claims one life every single minute: HIV/AIDS. 'Scientific breakthroughs have brought a once-distant dream within reach,' Trump exclaimed. 'My budget will ask Democrats and Republicans to make the needed commitment to eliminate the HIV epidemic in the United States within 10 years. We have made incredible strides.' Then, he added, 'we will defeat AIDS in America and beyond.' That was then and this is now. Last week, a group of scientists working on promising HIV vaccine studies were reportedly informed that the administration plans to revoke their research grants in a move experts warn could set the movement back years. When the global AIDS crisis peaked in the early 2000s, roughly 5,000 people were dying every single day from the disease. Thanks to the leadership of governments, the private sector, and philanthropists, the world invested more resources into the AIDS fight than ever before. This spurred nearly two decades of progress—not just against AIDS, but across global health broadly. Since 2004, AIDS-related deaths have been reduced by roughly two-thirds. But recently, progress has slowed. Covid-19 proved a major health disruption that reversed years of hard-fought gains. Efforts to reduce mother-to-child transmission rates have slowed. Global health funding is now under siege not just in the United States, but across Europe, too. And the world is no longer on track to meet critical 2030 AIDS targets. The great paradox here is that never in human history has there been more tools available to fight AIDS. The cost of antiretroviral drugs has fallen from $27 a day in 2000 to as little as 10 cents a day. Now, experts say what's needed to get the fight back on track—and eventually end the threat for good—isn't just better diagnostics and therapeutics, but long acting preventatives. Fortunately, it's an area that's seen great progress. Dubbed the 'breakthrough of the year' in 2024 by the journal Science, Gilead Science's lenacapavir is a long-acting injectable vaccine that has proven incredibly effective at preventing HIV infections. It represents a major step forward from the prevalent pre-exposure prophylaxis (PrEP) pill and mitigates some of the major privacy, stigma, and adherence issues that come with taking daily medication. The next step forward could be a vaccine with even longer immunity—one that gives patients lifetime protection. Researchers have been pursuing this laudable goal for years, but last week, the Trump administration announced plans to terminate research grants at two preeminent institutions, the Duke Human Vaccine Institute and the Scripps Research Institute, totaling $258 million. The researchers were told that the administration wanted 'to go with currently available approaches to eliminate HIV.' On the other hand, global health experts are warning that without new resources, President Trump's promise to end HIV within ten years is destined to fail—and when combined with the administration's other actions to cut and halt global health programs, HIV infections and deaths could actually rise for the first time in decades under his watch. 'I find it very disappointing that, at this critical juncture, the funding for highly successful H.I.V. vaccine research programs should be pulled,' Dennis Burton, an immunologist at Scripps, told The New York Times. Meanwhile AIDS groups, including the AIDS Vaccine Advocacy Coalition described the decision as inconceivable and shortsighted. The grant news marks the latest blow to the HIV/AIDS community, which has endured devastating domestic and global funding cuts in Trump's second term. San Francisco, which was one of the first epicenters of the domestic AIDS fight, has long relied on funding from the federal government to support community-based health programs that help reduce HIV transmission. These initiatives have helped the city make outstanding progress against the disease, but Centers for Disease Control and Prevention (CDC) grant delays have threatened testing, treatment, and care continuity. Even southern states which President Trump won decisively, and which account for 50% of all new U.S. HIV infections, have not been spared. According to the Foundation for AIDS Research (amfAR), cuts to domestic HIV prevention programs could spark over 14,000 additional deaths from AIDS-related causes and 143,000 new HIV infections. Earlier this year, HHS closed its Office of Infectious Diseases & HIV policy that quarterbacked the government's domestic AIDS response. Abroad, global health programs have fared even worse. In January, the Trump administration halted funding for The President's Emergency Plan for AIDS Relief (PEPFAR), a bipartisan program that has saved over 26 million lives. In a congressional hearing last week, Secretary of State Marco Rubio said that, '85 percent of recipients are now receiving PEPFAR services.' He also said that no one has died as a result of the aid freeze, a notion journalists and health experts scoff at. According to Brooke Nichols, an infectious disease mathematical modeler and health economist at Boston University, over 57,000 adults and 6,000 children have died as a result of the PEPFAR funding freeze and the discontinuation of global health programs. Even if those numbers are inflated, as some have contended, the number of lives needlessly lost is still likely in the tens of thousands. While some experts remain hopeful that the recent cuts will eventually be restored, the prospect of an AIDS-free future that President Trump himself once espoused appears grim. "This is a decision with consequences that will linger. This is a setback of probably a decade for HIV vaccine research," Burton warned.

The Very Gay Life of Edmund White
The Very Gay Life of Edmund White

New York Times

time10 hours ago

  • New York Times

The Very Gay Life of Edmund White

Edmund White might have invented the unapologetic queer on the page. At least he did for me. Nothing coded gay, vaguely tragic; nothing furtive or metaphorical or obscured behind the billowing curtains of literary flounciness. I can still recall the thrill of spotting the cover of his 1983 novel 'A Boy's Own Story' in a rotating rack of paperbacks in a bookstore in my dull, conservative hometown, Marlborough, England. I must have been about 15. It was the mid-1980s, the thick of the AIDS plague, and gay men were being cast as vectors of their own destruction. It was a complicated time to be thinking about coming out. But here was a novel with a boy on the cover who looked close to my age, his thick glossy hair gently ruffled by the wind, his lips plump, his jaw strong. His tank top revealed the slope of his shoulders, the contours of his biceps. I'd never seen a cover or read a book that spoke to me like that. The fact that a gay teenager could exist in fiction blew my mind. The fact that one, like me, could exist in the world did, too. 'A Boy's Own Story' was daring not just because it placed a queer adolescent at its center, but also because it did so with sophistication, introspection and horniness. The narrator — clearly, as with all of his narrators, based on him — is vividly real. Ed White and I were later to become friends, when I had moved to New York and was editing Out magazine. This was not a surprise: Ed, who died on Tuesday at 85, was always very open to meeting young literary men. He was a raconteur and had stories for miles. I lapped them up. We all did. Talking frankly about sex was a hallmark of his writing.(Among his many nonfiction works was 'The Joy of Gay Sex,' a sex manual he co-wrote in 1977.) He always saw himself as a gay writer for gay readers, the distinction he drew between his generation of queer writers and those who came earlier, like Gore Vidal and James Baldwin. They might write gay characters, but they never seemed to be writing for gay readers. Ed was. Want all of The Times? Subscribe.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store